The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


DICP, The Annals of Pharmacotherapy: Vol. 25, No. 11, pp. 1171-1174.
© 1991 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Briceland, L.
Right arrow Articles by Bailie, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Briceland, L.
Right arrow Articles by Bailie, G.


Research Articles

Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS

LL Briceland and GR Bailie

The incidences of pentamidine-associated nephrotoxicity and hyperkalemia were determined from a retrospective review of records in AIDS patients using standard definitions for both toxicities. There were 37 patients, mean age 35.6 +/- 7.7 years and mean initial creatinine clearance (Clcr) 96 mL/min (1.6 mL/s). The mean pentamidine dose was 255 +/- 60 mg/d (3.87 +/- 0.33 mg/kg/d). The mean total dose was 2900 +/- 1600 mg given over 11.6 +/- 5.9 days (range 3-21 d). In 28 patients who were nephrotoxic (8 mild, 6 moderate, 14 severe), 27 episodes were possibly or probably pentamidine-associated. Total dose and days to nephrotoxicity onset were 1570 +/- 710 mg and 6.4 +/- 2.8 days (range 2-15 d), respectively. Nine patients became hyperkalemic (one required countermeasures) and all cases were pentamidine-associated. Total dose and days to hyperkalemia onset were 2510 +/- 1460 mg and 9.2 +/- 4.9 days (range 3-16 d), respectively. Mean baseline potassium increased and Clcr decreased significantly during therapy (from 4.2 to 4.9 mEq/L and from 96 to 70 mL/min, respectively). No correlation between nephrotoxicity or hyperkalemia and initial renal function was found, but significant correlations were found between the total pentamidine dose or duration and the percent of renal function remaining. AIDS patients have a high incidence of pentamidine-associated nephrotoxicity (up to 73 percent) and hyperkalemia (24 percent) with a trend to earlier onset of the former.


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
T. Sun and Y. Zhang
Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translation
Nucleic Acids Res., March 1, 2008; 36(5): 1654 - 1664.
[Abstract] [Full Text] [PDF]


Home page
Journal of Reinforced Plastics and CompositesHome page
B. Khan, R. M. V. G. K. Rao, and N. Venkataraman
Low Velocity Impact Fatigue Studies on Glass Epoxy Composite Laminates with Varied Material and Test Parameters-Effect of Incident Energy and Fibre Volume Fraction
Journal of Reinforced Plastics and Composites, November 1, 1995; 14(11): 1150 - 1159.
[Abstract]


Home page
Journal of Composite MaterialsHome page
E. Wu and J. Liau
Impact of Unstitched and Stitched Laminates by Line Loading
Journal of Composite Materials, November 1, 1994; 28(17): 1640 - 1658.
[Abstract]




homecopy help contact us subscription past issues search current issue
Copyright © 1991 by Harvey Whitney Books Company.